These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28782482)

  • 1. Drug Combination in Clinical Cancer Treatments.
    Lu DY; Lu TR; Yarla NS; Wu HY; Xu B; Ding J; Zhu H
    Rev Recent Clin Trials; 2017; 12(3):202-211. PubMed ID: 28782482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer Drug Combinations, How Far We can Go Through?
    Lu DY; Chen EH; Wu HY; Lu TR; Xu B; Ding J
    Anticancer Agents Med Chem; 2017; 17(1):21-28. PubMed ID: 27039923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics.
    Lu DY; Qu RX; Lu TR; Wu HY
    Rev Recent Clin Trials; 2017; 12(2):101-110. PubMed ID: 28190390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational oncology--mathematical modelling of drug regimens for precision medicine.
    Barbolosi D; Ciccolini J; Lacarelle B; Barlési F; André N
    Nat Rev Clin Oncol; 2016 Apr; 13(4):242-54. PubMed ID: 26598946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
    Bashraheel SS; Domling A; Goda SK
    Biomed Pharmacother; 2020 May; 125():110009. PubMed ID: 32106381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized medicine in oncology: a personal view with myths and facts.
    Beijnen JH; Schellens JH
    Curr Clin Pharmacol; 2010 Aug; 5(3):141-7. PubMed ID: 20406176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico drug combination discovery for personalized cancer therapy.
    Jeon M; Kim S; Park S; Lee H; Kang J
    BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolving potential of companion diagnostics.
    Khoury JD
    Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cancer stem cells as the therapeutic target of tomorrow].
    Hatina J
    Wien Med Wochenschr; 2017 Feb; 167(1-2):25-30. PubMed ID: 26943922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision or Personalized Medicine for Cancer Chemotherapy: Is there a Role for Herbal Medicine.
    Wang Z; Liu X; Ho RL; Lam CW; Chow MS
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27399658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drosophila as a novel therapeutic discovery tool for thyroid cancer.
    Das T; Cagan R
    Thyroid; 2010 Jul; 20(7):689-95. PubMed ID: 20578898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor microenvironment and cancer therapy resistance.
    Sun Y
    Cancer Lett; 2016 Sep; 380(1):205-15. PubMed ID: 26272180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
    Coyne GO; Takebe N; Chen AP
    Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine.
    Shinko D; Diakos CI; Clarke SJ; Charles KA
    Clin Pharmacol Ther; 2017 Oct; 102(4):599-610. PubMed ID: 28699186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploiting tumor vulnerabilities: epigenetics, cancer metabolism and the mTOR pathway in the era of personalized medicine.
    Muñoz-Pinedo C; González-Suárez E; Portela A; Gentilella A; Esteller M
    Cancer Res; 2013 Jul; 73(14):4185-9. PubMed ID: 23687347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. At the crossroads of cancer stem cells and targeted therapy resistance.
    Wang A; Qu L; Wang L
    Cancer Lett; 2017 Jan; 385():87-96. PubMed ID: 27816488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and scientific considerations in preoperative (neoadjuvant) chemotherapy.
    Frei E; Miller D; Clark JR; Fallon BG; Ervin TJ
    Recent Results Cancer Res; 1986; 103():1-5. PubMed ID: 3738192
    [No Abstract]   [Full Text] [Related]  

  • 19. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
    Albin N; Mc Leer A; Sakhri L
    Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.
    Masui K; Gini B; Wykosky J; Zanca C; Mischel PS; Furnari FB; Cavenee WK
    Carcinogenesis; 2013 Apr; 34(4):725-38. PubMed ID: 23455378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.